In silico analysis of new flavonoids from Pongamia pinnata with a therapeutic potential for age-related macular degeneration

被引:3
|
作者
Das, Srijan [1 ]
Tiwari, Gopal J. [2 ]
Ghosh, Anindita [3 ]
机构
[1] Med Coll & Hosp Kolkata, 88 Coll St, Kolkata 700073, W Bengal, India
[2] CSIR Natl Bot Res Inst, Rana Pratap Marg,POB 436, Lucknow 226001, Uttar Pradesh, India
[3] Chittaranjan Natl Canc Inst, Dept Oncogene Regulat, 37 SP Mukherjee Rd, Kolkata 700026, W Bengal, India
关键词
Macular degeneration; Receptors; Flavonoids; Docking; ADME; Antioxidant; Radical scavenging;
D O I
10.1007/s13205-020-02537-2
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Age-related macular degeneration (AMD) leads to progressive degeneration of the macula which ultimately results in the complete loss of central vision. The present study aims to identify the new therapeutic agents for curing AMD. In the present study we have isolated, and compared the activity of natural flavonoids (Karanjin, Karanjachromene, Pongachromene, Pongapin) from plant species Pongamia pinnata (L.) Pierre (Family: Fabaceae) with known flavonol, Quercetin, and a drug Pazopanib through in silico approaches. Chemical structures of isolated flavonoids passed the ADME and PASS analysis, showed drug-like properties without violation of Lipinski parameters. Molecular docking studies were also performed for all isolated flavonoids with the receptors responsible for AMD viz. P2X7, PPAR, RAGE, and TLR3. Docking scores of the flavonoids with the receptors were found to be comparable to that of Quercetin, and Pazopanib (drugs already known for AMD treatment). Among all the flavonoids, Karanjachromene [P2X7 (- 31.39)] and Pongachromene [PPAR (- 65.13), RAGE (- 43.42)] showed a very good binding affinity with receptors predicting them to be the new potent chemical entities for the treatment of AMD.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Dark matter: Developing a new nanoantioxidant-based therapeutic system for the treatment of age-related macular degeneration
    Kwon, Yong-Su
    Voinov, Maxim A.
    Zheng, Min
    Smirnov, Alex I.
    Han, Zongchao
    NANO TODAY, 2023, 50
  • [42] Binocular Refraction in Patients with Age-Related Macular Degeneration
    Skrbek, Matej
    COLLEGIUM ANTROPOLOGICUM, 2013, 37 : 153 - 156
  • [43] Intravitreal aflibercept for neovascular age-related macular degeneration
    Xu, David
    Kaiser, Peter K.
    IMMUNOTHERAPY, 2013, 5 (02) : 121 - 130
  • [44] Anecortave acetate in the treatment of age-related macular degeneration
    Kaiser, Peter K.
    Singh, Rishi P.
    EXPERT REVIEW OF OPHTHALMOLOGY, 2006, 1 (02) : 135 - 139
  • [45] Atrial Fibrillation as a Predictor of Age-Related Macular Degeneration
    Bunch, Kaden T.
    May, Heidi T.
    Knowlton, Kirk U.
    Bair, Tami L.
    Muhlestein, J. Brent
    Anderson, Jeffrey L.
    Ranjan, Ravi
    Steinberg, Benjamin A.
    Bunch, T. Jared
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2025,
  • [46] Preferred therapies for neovascular age-related macular degeneration
    Chiang, Allen
    Regillo, Carl D.
    CURRENT OPINION IN OPHTHALMOLOGY, 2011, 22 (03) : 199 - 204
  • [47] The treatment of age-related macular degeneration (AMD) in practice
    Gicquer, Marie-Claude Cabanel
    Tanguy, Maela
    Apicella, Christophe
    Charvier, Marianne
    Clavaud, Henri
    Lescarret, Bruno
    Neme, Brigitte
    Perrot, Pascal
    SANTE PUBLIQUE, 2013, 25 (03): : 315 - 324
  • [48] Targeting Tissue Lipids in Age-related Macular Degeneration
    Apte, Rajendra S.
    EBIOMEDICINE, 2016, 5 : 26 - +
  • [49] Prevalence of age-related macular degeneration among the elderly
    Rasoulinejad, Seyed Ahmad
    Zarghami, Amin
    Hosseini, Seyed Reza
    Rajaee, Neda
    Rasoulinejad, Seyed Elahe
    Mikaniki, Ebrahim
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2015, 6 (03) : 141 - 147
  • [50] Preferred therapies for neovascular age-related macular degeneration
    Lally, David R.
    Gerstenblith, Adam T.
    Regillo, Carl D.
    CURRENT OPINION IN OPHTHALMOLOGY, 2012, 23 (03) : 182 - 188